| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780697 | Gynecologic Oncology | 2018 | 7 Pages |
Abstract
Primary HGSOC have a slightly higher ESR1 than and a similar ER expression breast cancer where aromatase inhibitor maintenance is routine for decades. Here we demonstrate evidence for the usefulness of Letrozole in HGSOC, particularly in patients with chemotherapy resistance or residual disease.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
V. Heinzelmann-Schwarz, A. Knipprath Mészaros, S. Stadlmann, F. Jacob, A. Schoetzau, K. Russell, M. Friedlander, G. Singer, M. Vetter,